We appreciate the interest of Chen and colleagues on the observation of the study. 1 We agree that the natural history of pancreas cancer is well known and in general, longer wait time will lead to cancer progression. The challenge of planning for treatment of initially resectable pancreas cancer is that some of the patients who undergo resection will be found to have metastatic disease in the post-operative period. As outlined in the discussion, the apparent better survival observed in the patients who waited longer than 12 weeks allowed some of initially under staged patients do "declare" their true stage and prevented them from being included in the study.It is difficult to argue against timely surgical oncologic care for patients with resectable pancreas cancer. However, these results underscore the importance of correlation of accurate staging and survival in patients with pancreas cancer. Furthermore, they highlight the limitations of current imaging in accurately staging such patients and in principle, support the argument of neoadjuvant chemotherapy for such patients.